These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
919 related articles for article (PubMed ID: 26315354)
1. Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer. Ramus SJ; Song H; Dicks E; Tyrer JP; Rosenthal AN; Intermaggio MP; Fraser L; Gentry-Maharaj A; Hayward J; Philpott S; Anderson C; Edlund CK; Conti D; Harrington P; Barrowdale D; Bowtell DD; Alsop K; Mitchell G; ; Cicek MS; Cunningham JM; Fridley BL; Alsop J; Jimenez-Linan M; Poblete S; Lele S; Sucheston-Campbell L; Moysich KB; Sieh W; McGuire V; Lester J; Bogdanova N; Dürst M; Hillemanns P; ; Odunsi K; Whittemore AS; Karlan BY; Dörk T; Goode EL; Menon U; Jacobs IJ; Antoniou AC; Pharoah PD; Gayther SA J Natl Cancer Inst; 2015 Nov; 107(11):. PubMed ID: 26315354 [TBL] [Abstract][Full Text] [Related]
2. Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer. Couch FJ; Shimelis H; Hu C; Hart SN; Polley EC; Na J; Hallberg E; Moore R; Thomas A; Lilyquist J; Feng B; McFarland R; Pesaran T; Huether R; LaDuca H; Chao EC; Goldgar DE; Dolinsky JS JAMA Oncol; 2017 Sep; 3(9):1190-1196. PubMed ID: 28418444 [TBL] [Abstract][Full Text] [Related]
3. Germline mutations in BRIP1 and PALB2 in Jewish high cancer risk families. Catucci I; Milgrom R; Kushnir A; Laitman Y; Paluch-Shimon S; Volorio S; Ficarazzi F; Bernard L; Radice P; Friedman E; Peterlongo P Fam Cancer; 2012 Sep; 11(3):483-91. PubMed ID: 22692731 [TBL] [Abstract][Full Text] [Related]
4. Pathologic findings in breast, fallopian tube, and ovary specimens in non-BRCA hereditary breast and/or ovarian cancer syndromes: a study of 18 patients with deleterious germline mutations in RAD51C, BARD1, BRIP1, PALB2, MUTYH, or CHEK2. Schoolmeester JK; Moyer AM; Goodenberger ML; Keeney GL; Carter JM; Bakkum-Gamez JN Hum Pathol; 2017 Dec; 70():14-26. PubMed ID: 28709830 [TBL] [Abstract][Full Text] [Related]
5. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals. Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067 [TBL] [Abstract][Full Text] [Related]
6. Germline mutations in cancer susceptibility genes in high grade serous ovarian cancer in Serbia. Krivokuca A; Boljevic I; Jovandic S; Magic Z; Mandic A; Tomasevic Z; Brankovic-Magic M J Hum Genet; 2019 Apr; 64(4):281-290. PubMed ID: 30651582 [TBL] [Abstract][Full Text] [Related]
7. BRIP1 as an ovarian cancer susceptibility gene: ready for the clinic? Balmaña J; Domchek SM J Natl Cancer Inst; 2015 Nov; 107(11):. PubMed ID: 26315355 [No Abstract] [Full Text] [Related]
8. Frequency of germline PALB2 mutations among women with epithelial ovarian cancer. Kotsopoulos J; Sopik V; Rosen B; Fan I; McLaughlin JR; Risch H; Sun P; Narod SA; Akbari MR Fam Cancer; 2017 Jan; 16(1):29-34. PubMed ID: 27631815 [TBL] [Abstract][Full Text] [Related]
9. Detection of Germline Mutations in Patients with Epithelial Ovarian Cancer Using Multi-gene Panels: Beyond BRCA1/2. Eoh KJ; Kim JE; Park HS; Lee ST; Park JS; Han JW; Lee JY; Kim S; Kim SW; Kim JH; Kim YT; Nam EJ Cancer Res Treat; 2018 Jul; 50(3):917-925. PubMed ID: 29020732 [TBL] [Abstract][Full Text] [Related]
11. Dominant-negative pathogenic variant BRIP1 c.1045G>C is a high-risk allele for non-mucinous epithelial ovarian cancer: A case-control study. Flaum N; van Veen EM; Smith O; Amico S; Newman WG; Crosbie EJ; Edmondson R; Smith MJ; Evans DG Clin Genet; 2022 Jan; 101(1):48-54. PubMed ID: 34585738 [TBL] [Abstract][Full Text] [Related]
12. Modification of ovarian cancer risk by BRCA1/2-interacting genes in a multicenter cohort of BRCA1/2 mutation carriers. Rebbeck TR; Mitra N; Domchek SM; Wan F; Chuai S; Friebel TM; Panossian S; Spurdle A; Chenevix-Trench G; ; Singer CF; Pfeiler G; Neuhausen SL; Lynch HT; Garber JE; Weitzel JN; Isaacs C; Couch F; Narod SA; Rubinstein WS; Tomlinson GE; Ganz PA; Olopade OI; Tung N; Blum JL; Greenberg R; Nathanson KL; Daly MB Cancer Res; 2009 Jul; 69(14):5801-10. PubMed ID: 19584272 [TBL] [Abstract][Full Text] [Related]
13. Mutation status of RAD51C, PALB2 and BRIP1 in 100 Japanese familial breast cancer cases without BRCA1 and BRCA2 mutations. Sato K; Koyasu M; Nomura S; Sato Y; Kita M; Ashihara Y; Adachi Y; Ohno S; Iwase T; Kitagawa D; Nakashima E; Yoshida R; Miki Y; Arai M Cancer Sci; 2017 Nov; 108(11):2287-2294. PubMed ID: 28796317 [TBL] [Abstract][Full Text] [Related]
14. BRIP1 loss-of-function mutations confer high risk for familial ovarian cancer, but not familial breast cancer. Weber-Lassalle N; Hauke J; Ramser J; Richters L; Groß E; Blümcke B; Gehrig A; Kahlert AK; Müller CR; Hackmann K; Honisch E; Weber-Lassalle K; Niederacher D; Borde J; Thiele H; Ernst C; Altmüller J; Neidhardt G; Nürnberg P; Klaschik K; Schroeder C; Platzer K; Volk AE; Wang-Gohrke S; Just W; Auber B; Kubisch C; Schmidt G; Horvath J; Wappenschmidt B; Engel C; Arnold N; Dworniczak B; Rhiem K; Meindl A; Schmutzler RK; Hahnen E Breast Cancer Res; 2018 Jan; 20(1):7. PubMed ID: 29368626 [TBL] [Abstract][Full Text] [Related]
15. Clinical utility of hereditary cancer panel testing: Impact of PALB2, ATM, CHEK2, NBN, BRIP1, RAD51C, and RAD51D results on patient management and adherence to provider recommendations. Vysotskaia V; Kaseniit KE; Bucheit L; Ready K; Price K; Johansen Taber K Cancer; 2020 Feb; 126(3):549-558. PubMed ID: 31682005 [TBL] [Abstract][Full Text] [Related]
16. Variants of cancer susceptibility genes in Korean BRCA1/2 mutation-negative patients with high risk for hereditary breast cancer. Park JS; Lee ST; Nam EJ; Han JW; Lee JY; Kim J; Kim TI; Park HS BMC Cancer; 2018 Jan; 18(1):83. PubMed ID: 29338689 [TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of Population-Based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 Mutation Testing in Unselected General Population Women. Manchanda R; Patel S; Gordeev VS; Antoniou AC; Smith S; Lee A; Hopper JL; MacInnis RJ; Turnbull C; Ramus SJ; Gayther SA; Pharoah PDP; Menon U; Jacobs I; Legood R J Natl Cancer Inst; 2018 Jul; 110(7):714-725. PubMed ID: 29361001 [TBL] [Abstract][Full Text] [Related]
18. Variant Identification in BARD1, PRDM9, RCC1, and RECQL in Patients with Ovarian Cancer by Targeted Next-generation Sequencing of DNA Pools. Suszynska M; Ratajska M; Galka-Marciniak P; Ryszkowska A; Wydra D; Debniak J; Jasiak A; Wasag B; Cybulski C; Kozlowski P Cancer Prev Res (Phila); 2022 Mar; 15(3):151-160. PubMed ID: 34906988 [TBL] [Abstract][Full Text] [Related]
19. Germline genetic variants in men with prostate cancer and one or more additional cancers. Pilié PG; Johnson AM; Hanson KL; Dayno ME; Kapron AL; Stoffel EM; Cooney KA Cancer; 2017 Oct; 123(20):3925-3932. PubMed ID: 28657667 [TBL] [Abstract][Full Text] [Related]